Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note released on Tuesday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 2.4 %

Shares of NASDAQ AWH opened at $0.75 on Tuesday. The business’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $1.35. The company has a market cap of $12.01 million, a PE ratio of -0.62 and a beta of 1.44. Aspira Women’s Health has a twelve month low of $0.67 and a twelve month high of $5.65.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. 12.19% of the stock is owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.